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Background: Breast cancer is a heterogeneous disease with a highly variable clinical outcome in which both
genetic and epigenetic changes have critical roles. We investigated tumor expression levels of histone-modifying
enzymes LSD1, HDAC2 and SIRT1 in relation with patient survival and tumor relapse in a retrospective cohort of
460 breast cancer patients. Additionally, we correlated expression levels with tumor differentiation and tumor cell
proliferation.
Methods: Immunohistochemical staining for LSD1, HDAC2 and SIRT1 was performed on tissue microarrays of
tumor and corresponding normal formalin-fixed paraffin-embedded tissues from breast cancer patients. Median
nuclear expression levels in tumor tissues were used to divide the patients into low and high expression categories.
In combined expression analyses, patients were divided into four subgroups: 1, all enzymes below-median; 2, one
enzyme above-median; 3, two enzymes above-median; 4, all three enzymes above-median. The Cox proportional
hazard model was used for univariate and multivariate survival analyses. The Pearson Chi-square method was used
to assess correlation of combined expression levels with tumor cell proliferation and tumor differentiation.
Results: Expression of LSD1 and SIRT1, but not of HDAC2, was significantly increased in tumor tissues compared to
their normal counterparts (both p < 0.001). Multivariate survival analyses identified SIRT1 as independent prognostic
factor for relapse-free survival (RFS) with a hazard ratio (HR) of 1.34 (95% CI = 1.04-1.74, p = 0.02). For overall survival
(OS), no significant differences were found when the individual enzymes were analyzed. Analyses of combined
expression levels of the three histone-modifying enzymes correlated with OS (p = 0.03) and RFS (p = 0.006) with a
HR of respectively 1.49 (95% CI = 1.07-2.08) and 1.68 (95% CI = 1.16-2.44) in multivariate analyses and were also
related to tumor differentiation (p < 0.001) and tumor cell proliferation (p = 0.002).
Conclusions: When the combined expression levels were analyzed, high expression of LSD1, HDAC2 and SIRT1
showed shorter patient survival time and shorter time to tumor relapse and correlated with poor tumor
differentiation and a high level of tumor cell proliferation. Expression of these histone-modifying enzymes might
therefore be involved in breast cancer pathogenesis.
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Clinical outcome of breast cancer patients is widely vari-
able, due to the molecular heterogeneity of breast cancer.
Breast cancer classification is based on a combination of
several clinicopathological parameters, including histo-
pathology, tumor stage, tumor grade and hormone re-
ceptor status and are used to guide treatment of breast
cancer patients [1]. Even so, both over- and undertreat-
ment of individual breast cancer patients occur, due to
lack of reliable biomarkers [2,3]. In order to further sub-
classify breast cancer patients, new prognostic bio-
markers are warranted to improve the prognosis of
individual breast cancer patients, based on their tumor
characteristics. Such molecular biomarkers can be de-
rived from biological mechanisms that underlie tumor
growth and development.
Epigenetics is a rapidly developing field of research. Epi-
genetic mechanisms include DNA methylation, histone-
modifying enzymes and their histone modifications. Due
to the reversible nature of these processes, they are attract-
ive targets for drug development and could be exploited to
find novel prognostic biomarkers [3]. Histone-modifying
enzymes are responsible for modification of certain resi-
dues on histone tails (histone modifications), thereby regu-
lating DNA accessibility and expression of specific genes.
Aberrant expression of histone-modifying enzymes, in-
cluding lysine-specific demethylase 1 (LSD1), histone
deacetylase 2 (HDAC2) and silent mating-type informa-
tion regulation 2 homologue 1 (SIRT1), has been shown
to have a role in breast cancer development [4-9] as well
as prognostic value for breast cancer [10]. LSD1 is the
first identified histone demethylase involved in specific
demethylation of mono- and dimethylated lysine 4 on
histone 3 (H3K4) and lysine 9 on histone 3 (H3K9) [4],
and has been shown to increase with tumor progression
[5]. HDAC2 is part of the class I HDACs and is respon-
sible for deacetylation of histones and other protein tar-
gets [6]. Deacetylation of histones leads to compaction
of the chromatin (heterochromatin) and reduced tran-
scription of genes, including genes involved in processes
such as cellular proliferation and cellular differentiation
[6]. HDAC inhibition is currently investigated in clinical
trials aiming to reverse hormone resistance in breast
cancer [7]. SIRT1 deacetylates several histones and plays
a role in tumorigenesis [8] and expression levels were
increased in breast tumors compared to their matched
normal breast tissues [9]. Recently, two publications
showed that both histone demethylation inhibitors and
histone deacetylation inhibitors, and especially a combin-
ation of the two agents, inhibit breast cancer cell growth
in vitro [11,12], suggesting an important role for histone
demethylases and deacetylases in breast cancer.
LSD1, HDAC2 and SIRT1 are shown to act together
in a single complex that represses transcription throughcompaction of the chromatin [13], thereby regulating
gene expression. Therefore, we hypothesized that the com-
bined expression levels of these collaborating histone-
modifying enzymes in breast tumors is a stronger predictor
for patient survival and tumor relapse than expression
levels of the individual enzymes. Therefore, we investigated
the correlation of the nuclear expression levels of LSD1,
HDAC2 and SIRT1 as well as the combined expression
levels of these enzymes with clinical outcome. The results
showed that the expression levels of LSD1 and SIRT1 were
increased in tumor tissues compared to adjacent normal
breast tissues. Furthermore, overall survival (OS) and
relapse-free survival (RFS) were decreased in breast
cancer patients when tumor cells expressed high levels
of all three markers. Finally, combined expression levels
of the histone-modifying enzymes LSD1, HDAC2 and




The patient population was a retrospective cohort of fe-
male breast cancer patients (TNM: I-III) who underwent
primary tumor resection at the Leiden University Medical
Center (LUMC) between 1985 and 1996 (n = 822), as de-
scribed previously [14]. Patients with bilateral tumors or a
prior history of cancer (other than basal cell carcinoma or
cervical carcinoma in situ) were excluded from the study.
The following data were retrieved and used as covariates
in multivariate analyses: age, tumor size, nodal status, ex-
pression of estrogen receptor (ER), progesterone receptor
(PgR), human epidermal growth factor 2 (HER2), tumor
grade, histological type, local and systemic therapy, sur-
vival time, and time until tumor relapse. All tumors were
graded and histologically classified according to patho-
logical standards by an experienced breast cancer patholo-
gist (V.S.). The study was conducted with anonymized
patient data according to Dutch law and in agreement
with the Dutch Code of Conduct: “Proper Secondary Use
of Human Tissue in the Netherlands” (Federation of
Medical Scientific Societies, the Netherlands, http://
www.federa.org/sites/default/files/bijlagen/coreon/code
propersecondaryuseofhumantissue1_0.pdf). The specific
section is paragraph one of chapter eight on page 43
and therefore we did not ask for approval of an ethics
committee [15], and according to the REMARK guide-
lines [16].
Study design
Formalin-fixed paraffin-embedded (FFPE) tumor tissue
of 701 patients, of whom tumor tissue was available, was
included into a tissue microarray (TMA), as described
previously [14]. For each patient, three cores of tumor
tissue were included. For 261 breast cancer patients, of
Table 1 Clinicopathological data of the 460 breast cancer
patients used in the study
Characteristic Mean (range) N = 460 %
Follow-up (years) 11.8 (0.16-27.55)





























Mastectomy without RT 180 39
Mastectomy with RT 97 21
BCS with RT 183 40
Systemic treatment
Chemotherapy alone 89 19
Endocrine therapy alone 77 17
Chemo- and endocrine therapy 18 4
None 276 60
Clinicopathological characteristics of the cohort of breast cancer patients.
Statistical analyses were performed with all patients (n = 460) with complete
clinicopathological data and nuclear staining data for LSD1, HDAC2 and SIRT1.
Tumor size (T) and nodal status (N) were based on the TNM staging criteria.
ER: estrogen receptor, PgR: progesterone receptor, HER2: human epidermal
growth factor receptor 2, RT: radiotherapy, BCS: breast conserving surgery.
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cores of normal breast tissue were included in separate
TMA blocks.
Immunohistochemistry
TMA sections were cut (4 μm) and processed for immu-
nohistochemistry (IHC). The antibodies that were used
for IHC were validated by several other research groups:
anti-LSD1 (ab17721, mouse, Abcam, Cambridge, United
Kingdom) [17,18], anti-HDAC2 (ab39669, rabbit, Abcam)
and anti-SIRT1 (ab32441, rabbit, Abcam) [19]. The IHC
was performed using a standard protocol [20]. Briefly, tis-
sues were deparaffinized in xylene and rehydrated in a
series of graded alcohol. Antigen retrieval was performed
by heating the sections for 10 min in sodium-citrate buffer
at 95°C (pH 6.0). Endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide solution for 20 mi-
nutes. Incubation, with an optimized concentration of the
antibodies described, was performed overnight at room
temperature. Envision + peroxidase labelled polymer
rabbit or mouse (Dako, Glostrup, Denmark) and DAB +
liquid substrate chromogen system (Dako) were used
for visualization of the expression levels. Counterstain-
ing was performed using haematoxylin and dehydration
was performed using graded alcohol and xylene.
Evaluation of immunohistochemistry
The scoring of the immunohistochemical staining was
performed by two investigators (A.S. and G.D.), who
were blinded for the clinicopathological data. The per-
centage of positive stained tumor cell nuclei was scored
in each of the tissue cores, from 0-100% with 10% incre-
ments. The second observer scored 30% of the tissue
cores in order to determine consistency in quantifica-
tion, which was tested with Cohen’s kappa coefficient for
inter-observer variability. A Cohen’s kappa coefficient >0.6
was considered as substantial agreement. In addition to
tumor tissues, stained normal epithelial breast tissue cores
were also evaluated using the same scoring criteria as de-
scribed above.
Statistical analysis
Data were analyzed using SPSS 20.0 for Windows (SPSS
Inc., Chicago, Illinois, United States of America). The
paired student’s t-test was used to compare expression
levels in tumor breast tissues and their corresponding
normal epithelial tissues of 60 individual patients. The
one-way ANOVA method was used for calculation of differ-
ences in expression levels between the TNM tumor stages
(I-III) for LSD1, HDAC2 and SIRT1. For survival analyses,
the patients were divided into a low and high expression
category based on the median percentage positive tumor
cell nuclei per enzyme. The Cox proportional hazards
model was used for univariate and multivariate survival
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dence curves were plotted to graphically show differences
in patient survival and tumor relapse between the groups
with different expression levels, respectively. For the uni-
and multivariate analyses, only patients with nuclear stain-
ing data for all three enzymes and all covariates available,
complete case analysis, were used in the statistical analyses
(n = 460). Data were censored when patients were alive or
free of relapse at their last follow-up date (lastly march
2013). Overall survival (OS) was defined as the time from
date of surgery until death from any cause. Relapse-free
survival (RFS) was defined as the time from surgery until
the occurrence of a local, regional or distant tumor relapse
or death by cancer. The Pearson Chi-square method was
used to test for correlations between the combined ex-
pression levels of LSD1, HDAC2 and SIRT1 and clinical
parameters. The low expression group was used as a refer-
ence in the single marker analyses. Low expression of all
three markers was used as reference in the analyses of the
combined expression levels. For the analyses of the com-
bined expression levels of the markers, the patients were
divided into four categories as follows: all enzymes below-
median expression (‘all-low’), one enzyme above-median
expression, two enzymes above-median expression and all
three enzymes above-median expression (‘all-high’). We
performed a Chi-square test between the four patients
groups and all variables used as covariates, which are well-
known independent prognostic factors in breast cancer
and we corrected for those covariates in the multivariateFigure 1 LSD1, HDAC2 and SIRT1 expression in breast cancer. Express
determined in breast tumors as percentage of tumor cells with positive nu
expression level, for low and high expression were 85% for LSD1, 80% for H
tissue core (left), a tumor tissue core with expression above median (middl
tissue cores were taken with a 100× magnification and a zoomed-in sectio
(400× magnification). The brown color represents the expression level of thanalyses. For all analyses, a two-sided p-value ≤0.05 was
considered statistically significant.
Results
Immunohistochemical staining of LSD1, HDAC2 and SIRT1
in breast tumors
Table 1 shows the clinicopathological data of the breast
cancer patients (n = 460) used for the statistical analyses
of the three markers. The mean follow-up time was
11.8 years (range: 0.16-27.55 years) and the mean age at
diagnosis was 58.3 years (range: 23–89 years). Percent-
ages of positive nuclei for LSD1, HDAC2 and SIRT1 in
the tumor and normal tissue cores were determined by
IHC. Figure 1 shows representative pictures of normal
breast tissue cores immunohistochemically stained indi-
vidually for each enzyme, as well as representative pic-
tures of breast cancer tissue cores with expression above
and below median for each of the enzymes. The brown
color is the amount of expression of the enzyme. The
median percentages of positive tumor nuclei, used for
the statistical analyses, were 85% for LSD1, 80% for
HDAC2 and 70% for SIRT1. Cohen’s kappa coefficient
was calculated to determine the inter-observer variability.
The kappa coefficients for scoring of the tumor tissues
were 0.664 for LSD1 and 0.627 for SIRT1. Both kappa
coefficients were considered as substantial agreement
between the observers. For staining of HDAC2 in
tumor tissues, the kappa for scoring of the tumor tis-
sue was not considered as substantial agreement.ion levels of LSD1, HDAC2 and SIRT1 were immunohistochemically
clear staining. The respective cut-off values, based on the median
DAC2 and 70% for SIRT1. For each staining a representative normal
e) and below median (right) is shown. Pictures of the 0.6 mm tumor
n of the tumor tissue cores is shown on the right of each image
e enzymes.
Derr et al. BMC Cancer 2014, 14:604 Page 5 of 11
http://www.biomedcentral.com/1471-2407/14/604Therefore, a re-evaluation of the scoring was performed
by the two observers until agreement was reached. For
normal tissues the kappa coefficients were 0.693 for LSD1,
0.628 for HDAC2 and 0.605 for SIRT1, which were all
considered as substantial agreement as well. The mean
percentage of positive nuclei in the cores determined for
each patient by the first observer, was used for survival
analyses. Figure 2 shows the expression levels of LSD1,
HDAC2 and SIRT1 in normal breast tissues compared
to tumor tissues. Analyses of paired tumor and normal
tissues showed an increased expression of LSD1 and
SIRT1 in tumor tissues compared to normal tissues
(both p < 0.001). HDAC2 expression did not signifi-
cantly differ in tumor tissues compared to normal tis-
sues (p = 0.4).
Correlation of LSD1, HDAC2 and SIRT1 expression in
tumor tissue with tumor stage
To investigate whether expression of each of the histone-
modifying enzymes was related to the TNM tumor stage,
the mean percentage of positive tumor nuclei was plottedFigure 2 SIRT1, HDAC2 and LSD1 expression in breast tumor tissues
the mean percentage (horizontal line) of nuclei positive for LSD1, HDAC2 a
breast cells (labeled “T”) for 60 patients with expression data of the histone
Outliers are represented by circles. P-values were calculated using a pairedagainst tumor stage. Figure 3 shows the percentage of
positive nuclei in each tumor stage (I-III) for LSD1,
HDAC2 and SIRT1. A one-way ANOVA analysis showed
significant differences between the tumor stages for LSD1
(p < 0.001) and SIRT1 (p = 0.04) (Figures 3A and 3C).
With higher expression in patients diagnosed with a
higher tumor stage. HDAC2 did not show a significant
difference between the tumor stages (p = 0.4) (Figure 3B).
Prognostic value of single markers
Univariate analyses showed significant differences in patient
survival and tumor relapse between patients with high and
low nuclear expression of LSD1 (OS: p = 0.002, HR = 1.42,
95% CI = 1.13-1.77; RFS: p = 0.001, HR = 1.55, 95% CI =
1.20-1.99) and SIRT1 (RFS: p = 0.03, HR = 1.32, 95% CI =
1.03-1.70) (Figures 4A, 4C and 4D). No significant differ-
ences were observed for HDAC2 expression (OS: p = 0.1,
HR = 1.23, 95% CI = 0.99-1.54; RFS: p = 0.1, HR = 1.25,
95% CI = 0.98-1.61) (Figure 4B and 4D). Multivariate ana-
lyses of the expression levels for individual markers showed
a significant difference in RFS for SIRT1 (p = 0.02, HR =compared with normal epithelial breast tissues. The boxplots show
nd SIRT1 in normal epithelial breast cells (labeled “N”) versus tumor
-modifying enzymes for tumor tissues and normal epithelial tissues.
student’s t-test and p-values ≤0.05 are considered as significant.
Figure 3 (See legend on next page.)
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Figure 3 Expression of LSD1, HDAC2 and SIRT1 in different tumor stages. We included 182 patients with a stage I disease, 227 patients
with a stage II disease and 51 patients with a stage III tumor. (A) Boxplot showing the percentage of positive tumor cells for LSD1 versus the
TNM tumor stage (I-III) at moment of diagnosis. (B) HDAC2 expression levels versus TNM tumor stage shown in a boxplot. (C) The expression
levels of SIRT1 versus TNM tumor stage represented in a boxplot. The thick horizontal lines represent the mean percentage of positive tumor cells
in each category. Outliers are represented by circles. The p-values were calculated using the one-way ANOVA method and p-values ≤0.05 are
considered as significant.
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pression group (Figure 4D). No significant differences were
observed for HDAC2 (OS: p = 0.6, HR = 1.07, 95% CI =
0.85-1.34; RFS: p = 0.2, HR = 1.16, 95% CI = 0.90-1.50) and
LSD1 (OS: p = 0.2, HR = 1.18, 95% CI = 0.94-1.50; RFS: p =
0.1, HR = 1.23, 95%CI = 0.94-1.60) in the multivariate ana-
lyses (Figure 4D).
Prognostic value of the markers combined
Since the three enzymes work together in one complex,
we hypothesized that the combined expression levels ofFigure 4 Overall and relapse-free survival analyses of the expression
univariate relapse-free survival (RFS) analysis of LSD1 (A), HDAC2 (B), and S
expression level below median or equal to median and ‘high expression’ w
their 95% confidence intervals (95% CI) and their corresponding p-values fo
were evaluated with the Cox proportional hazard model for uni- and multithe three histone-modifying enzymes is a stronger pre-
dictor for patient survival and tumor relapse than ex-
pression of individual enzymes. Survival analyses of OS
and RFS showed that the combined expression level of
LSD1, HDAC2 and SIRT1 in breast tumors was more
predictive for patient survival and tumor relapse than
each of the individual markers separately in both univar-
iate and multivariate analyses (Figure 5). Chi-square ana-
lyses showed that there were significant differences
between the four patient groups in ER (p = 0.019), PgR
(p = 0.007), tumor grade (p < 0.001) and systemic therapylevels LSD1, HDAC2 and SIRT1. Cumulative incidence curves of the
IRT1 (C) in breast tumors (n = 460). ‘Low expression’ was defined as
as defined as expression level above median. (D) Hazard ratios (HR),
r LSD1, HDAC2, and SIRT1 expression for overall survival (OS) and RFS
variate analysis. Significant p-values (≤0.05) are indicated in bold.
Figure 5 Survival analyses of the combined expression levels of LSD1, HDAC2 and SIRT1. Univariate Kaplan-Meier (KM) plot showing
overall survival (OS) (A) and a cumulative incidence curve showing relapse-free survival (RFS) (B) of breast cancer patients for the combined
expression levels of LSD1, HDAC2 and SIRT1. The patients were categorized in four subgroups depending on the expression levels of the histon-modifying
enzymes. Subgroups: ‘All low’: expression of all three enzymes below median, ‘1 high’: one of the enzymes expressed above median, ‘2 high’: two
enzymes expressed above median, ‘all high’: all three enzymes expressed above median. (C) The Cox proportional hazard model was used for
evaluation of the HRs and the 95% confidence intervals (95% CI) of the combined expression levels of LSD1, HDAC2 and SIRT1 for OS and RFS in the
four subgroups. Significant p-values (≤0.05) are indicated in bold.
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analyses. Multivariate analyses of the combined marker
expression levels showed that patients with high expres-
sion level of all three markers had a shorter OS compared
to patients with low expression of all the enzymes (p =
0.03, HR = 1.49, 95% CI = 1.07-2.08) (Figure 5C). For RFS
the HR was 1.68 (p = 0.006, 95% CI = 1.16-2.44) in the
‘all-high’ expression group versus the ‘all-low’ expression
group (Figure 5C). This result indicated that patients with
high expression of all three enzymes have a shorter RFS
compared to patients with one or more enzymes with a
low expression level.
Correlation of the combined expression levels of LSD1,
HDAC2 and SIRT1 with tumor differentiation and tumor
cell proliferation
We tested if there was a correlation between the com-
bined expression levels of the three enzymes and tumor
differentiation, a marker of aggressive tumors, in the
whole study population. Indeed, a significant correlation
between these expression levels and tumor differenti-
ation was found (p < 0.001; Table 2). The results showed
that 24% of the patients with low expression of all threeenzymes had a well-differentiated tumor and only 12%
of the patients with high expression of all three enzymes
had a well-differentiated tumor. A low differentiation
grade was found in 21% of patients with low expression
of LSD1, HDAC2 and SIRT1 and 43% of the patients
with high expression of all three enzymes had a low
grade of tumor differentiation. In addition, we investi-
gated the relation between the combined expression
levels of LSD1, HDAC2 and SIRT1 and tumor cell pro-
liferation, assessed by ki-67 expression, which is another
marker of aggressive tumors. Ki-67 expression levels
were determined by IHC previously in our study cohort
[21] and data were available for 423 of 460 patients
(92%). A significant correlation was found between the
expression of ki-67 and the combined expression levels
of the three enzymes (p = 0.002; Table 3). The results
showed that in 68% of the patients with low expression
of all three enzymes, there was no expression of ki-67,
which indicated that there is only a low level of tumor
cell proliferation in these patients. When at least one
of the three histone-modifying enzymes showed high
expression, we observed an increase in the percentage
of ki-67 positive tumors (up to 56%), indicating more
Table 2 Correlation between combined expression level of LSD1, HDAC2 and SIRT1 and tumor differentiation
N = 460 3× low 1× high 2× high 3× high Total
Tumor differentiation
High 31 (23.7%) 9 (8.4%) 21 (15.4%) 10 (11.6%) 71 (15.4%)
Moderate 73 (55.7%) 52 (49.1%) 58 (42.3%) 39 (45.4%) 222 (48.3%)
Low 27 (20.6%) 45 (42.5%) 58 (42.3%) 37 (43.0%) 167 (36.3%)
Total 131 106 137 86 460
Chi-square: p < 0.001
Tumor differentiation, according to tumor grade as assessed by an experienced pathologist, versus the combined expression levels of LSD1, HDAC2 and SIRT1 in
460 breast cancer patients are shown. Patients were divided in four subgroups based on the expression levels of the histone-modifying enzymes: all enzymes
below median (3x low), one enzyme above median (1× high), two enzymes above median (2× high) and all three enzymes above median (3x high).
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summary, there are correlations between the com-
bined expression levels of LSD1, HDAC2 and SIRT1
and tumor differentiation and between the combined
expression levels of these enzymes and tumor cell
proliferation.
Discussion
Our study identified combined expression levels of the
histone-modifying enzymes LSD1, HDAC2 and SIRT1 as
an independent prognostic factor for patient survival
and tumor relapse in breast cancer patients. In addition,
our results showed that the combined marker expression
levels correlated with tumor differentiation and tumor
cell proliferation. All these results implicated that high
expression of all three enzymes is associated with a more
aggressive phenotype of the breast tumors.
Histone-modifying enzymes are involved in numerous
processes that are related to cancer, including cellular
proliferation and differentiation [22]. There is increasing
evidence that shows that aberrant expression of these
enzymes has a role in (breast) cancer development and
tumor growth [5,6,8,9,23]. LSD1 is overexpressed in vari-
ous cancer types, such as bladder, lung and colorectal
cancer [23]. In our breast cancer patient study cohort,
an increase in the expression of LSD1 in tumor tissues
was found compared with normal epithelial breast tis-
sues. Our study also showed an increase in nuclear ex-
pression of LSD1 from tumor stage I to III, which has
been described in literature by another group as well [5].Table 3 Correlation between combined expression level of LS
N = 423 3× low 1× high
Ki-67
No expression 81 (67.5%) 40 (44.0%)
Expression 39 (32.5%) 51 (56.0%)
Total 120 91
Chi-square: p = 0.002
Ki-67 expression versus the combined expression levels of LSD1, HDAC2 and SIRT1
categories based on the expression levels of the histone-modifying enzymes: all en
enzymes above median (2× high) and all three enzymes above median (3× high).Furthermore, we demonstrated that SIRT1 expression
levels were significantly increased in tumor tissues com-
pared to normal epithelial breast tissues, which has also
been described in literature [9]. The multivariate Cox
proportional hazard analyses showed that SIRT1 expres-
sion was an independent prognostic factor for RFS, but
not for OS in our breast cancer cohort, although a previ-
ous publication showed prognostic value for both [10].
This discrepancy can be explained by differences be-
tween patient cohorts, because our cohort contained
older patients and we excluded patients with a TNM
tumor stage IV disease from the study. In our cohort,
HDAC2 expression was not significantly different in
normal and tumor breast tissues and was not predictive
for OS and RFS, confirming the results of the univariate
OS analysis of Müller et al. [24].
Other groups have studied combinations of histone-
modifying enzymes, but did not correlate these to clin-
ical outcome. For example, Huang et al. showed in vitro
that LSD1 and HDACs are involved in tumor cell prolif-
eration, because synergistic inhibition of breast cancer
cell proliferation was observed as compared to inhibition
of the individual enzymes [11]. In the same study, micro-
array screening showed that inhibition of the enzymes
led to reexpression of aberrantly silenced genes involved
in processes such as cell differentiation and cell prolifer-
ation, which are frequently deregulated in breast cancer
[11].
Our study is, to our knowledge, the first study that cor-
related the combined nuclear expression levels of theseD1, HDAC2 and SIRT1 and ki-67 expression
2× high 3× high total
67 (51.1%) 37 (45.7%) 225 (53.2%)
64 (48.9%) 44 (54.3%) 198 (46.8%)
131 81 423
in 423 breast cancer patients are shown. Patients were divided into four
zymes below median (3x low), one enzyme above median (1× high), two
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breast cancer patients. High expression of all three en-
zymes in tumor cells was correlated with reduced patient
survival and shortened RFS compared to the expression
level of the individual enzymes, implicating that LSD1,
HDAC2 and SIRT1 act together in the same complex.
It has been shown in literature that all three histone-
modifying enzymes, analyzed in our study, are individually
involved in inhibition of functioning of p53 via direct
modification of p53 (demethylation by LSD1 [25] and dea-
cetylation by SIRT1 [26]) or inhibition of p53-DNA bind-
ing (HDAC2 [27]). p53 is a well-known tumor-suppressor
and reduced functioning of p53 leads to reduced apop-
tosis, reduced cellular senescence and increased survival
of cells with DNA-damage, due to reduced cell-cycle ar-
rests, potentially leading to tumor development [25-27].
Therefore, we hypothesize that the complex of LSD1,
HDAC2 and SIRT1 has important roles, next to chroma-
tin repression, in regulating cell survival and that aberrant
expression of this complex leads to sustained survival of
tumor cells. Possibly, combined inhibition of multiple
histone-modifying enzymes, such as LSD1, HDAC2 and
SIRT1, could lead to improved treatment of breast cancer
patients.
Conclusions
In summary, we showed that the combined expression
level of LSD1, HDAC2 and SIRT1 is a good predictor
for OS and RFS in breast cancer patients. High expression
of all three enzymes correlated with a more aggressive
tumor phenotype, which makes this multi-enzyme com-
plex an interesting target for breast cancer treatment.
Future research for prognostic biomarkers should focus
on analyses of such combinations of histone-modifying
enzymes, acting together in multi-protein complexes,
and their respective histone modifications. This can po-
tentially further elucidate the complex epigenetic regu-
latory mechanisms in breast cancer, which will help
identifying new targets for therapy.
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